INTRODUCTION
============

Breast cancer is the most common cancer and a major cause of death among women worldwide^\[[@B1]\]^. Thousands of new cases of breast cancer are diagnosed annually in Iran, which imposes a major burden on the health sector^\[[@B2],[@B3]\]^. Breast cancer is classified into three main subsets of gene expression: luminal (A and B), basal-like, and Her2/neu-overexpressing^\[[@B4]\]^. TNBC is characterized by the absence of the expression of Her2, PRs, and ERs^\[[@B4]\]^. TNBC is a very aggressive subtype with a poor prognosis compared to other types of breast cancer, but accounts for less than 20% of cases. It has been shown that patients with TNBC have larger tumors, and a higher grade and invasion of the lymph nodes^\[[@B5]\]^. Studies have also displayed that only 20%-30% of the patients respond to common treatments such as chemotherapy and radiotherapy. In the remaining cases, there is recurrence of disease and resistance to treatment within the first three years after diagnosis^\[[@B6],[@B7]\]^. A major problem related to breast cancer is late detection, especially in TNBCs, which are often diagnosed at advanced stages with a high histological grade^\[[@B8],[@B9]\]^. Another issue is the lack of reliable early diagnostic biomarkers for TNBC. Therefore, documentation of early-detection biomarkers and the introduction of novel therapies to enhance the pathologicl complete response rate in TNBC patients are of great importance and need to be considered seriously.

Epigenetic variations have been demonstrated to play a role in the progress of breast cancer. These changes are involved in the expression of genes and, thus, disrupt the signaling pathways^\[[@B10]\]^. One of the most important mechanisms of epigenetics that causes cancer is histone change. The changes in histone structure due to environmental variations in different geographical regions and ethnicities can be dissimilar. Researchers are currently studying HDAC and its inhibitors. Recent investigations have displayed a direct correlation between breast tumors and differences in histone proteins^\[[@B11],[@B12]\]^.

Equilibrium between the acetylation and deacetylation of nuclear histones is essential for the regulation of gene expression. These reactions are induced by HDAC and histone acetyltransferase, respectively. Aberrant expression of HDAC, also known as lysine deacetylase, has been linked to tumor progression, prognosis, and pathogenesis^\[[@B13],[@B14]\]^. Class I HDACs are expressed in most tissues and include HDAC 1, 2, 3, and 8. The aberrant expression of class I HDAC has been shown in gastric, esophageal, colorectal, prostate, breast, and lung cancers^\[[@B15]-[@B17]\]^. HDAC8 is a recently recognized subtype of class I HDAC, which is associated with several malignancies. HDAC8 inhibition in T-cell lymphoma increases apoptosis in these cells, and its overexpression plays a significant role in the pathogenesis of neuro-blastoma^\[[@B18]\]^. In recent years, attention has been focused on the targeted inhibition of HDAC8 to control and inhibit the cancer growth^\[[@B19]\]^.

Despite the well-recognized roles of HDAC8 in the progression of breast cancer, its diagnostic value has not been considered. The current study was conducted to evaluate the possible association between HDAC8 expression and clinical outcomes of patients with breast cancer. The relation of this gene with the pathologic findings of TNBC patients were compared with notes of nTNBC subjects. The diagnostic value of HDAC8 in differentiation between TNBC and nTNBC subjects was also assessed.

MATERIALS AND METHODS
=====================

**Patients**

Cancerous and adjacent normal tissue specimens were obtained from 50 patients with breast cancer who underwent surgery at Towhid Hospital in the city of Sanandaj in Iran between January 2016 and October 2018. The patients with breast cancer had an average age of 48.33 ± 9.5 years. None of the patients enrolled in this study had undergone pre-operative chemotherapy, radiotherapy, or any other treatment. Those with a history of tumors in other organs were excluded. The tumor, node, metastasis staging system and the Scarf-Bloom-Richardson criteria were used for staging and grading, respectively^\[[@B20],[@B21]\]^. All specimens were immediately frozen in liquid nitrogen and stored at -80 °C pending assay. Detailed clinical information of the enrolled patients is listed in [Table 1](#T1){ref-type="table"}.

**Immunohistochemistry** **assay**

Tissues were excised, and immunohistochemistry was carried out. The tissues were then examined for PR, Her2, and ER. Staining was performed according to the standard protocol^\[[@B22]\]^.

**RNA purification, cDNA synthesis, and qRT-PCR**

RNX-Plus kits (Cinnagen, Iran) were used to extract the total RNA from the breast cancer specimens and adjacent normal tissue, according to the instructions provided by the manufacturer. The quality and quantity of the samples were assessed photometrically and electrophoretically. A RevertAid First Strand cDNA Synthesis Kit (Fermenta, Thermo Scientific, USA) was used to synthesize the cDNA from the total RNA, as per manufacturer's instructions. Rotor-Gene 6000 (Corbett Research, Australia) was employed to perform qRT-PCR in triplicate in a 25-μL reaction volume consisting of 2× Maxima SYBR Green qPCR Master Mix buffer (Fermentas), 400 nM each of forward and reverse primer, and cDNA. Then 40 cycles of PCR were carried out as follows: 95 °C for 10 min for one cycle, 94 °C for 10 s, and 60 °C for 40 s. The expression of HPRT was utilized to normalize data from each group. The following primer pairs were also used for qPCR reaction: HDAC8 (FP) GGCTGCGGA ACGGTTTTAAG, HDAC8 (RP) GCTTCAATCAAA GAATGCACCATAC, HPRT (FP) CCTGGCGTCGT GATTAGTG, and HPRT (RP) TCAGTCCTGTCCAT AATTAGCC. The Ct values for each sample were determined with amplification plots in the logarithmic phase. The PCR outcome and efficiency of amplification were determined using LinRegPCR software V12.17 using the 2^−ΔΔCt^ method^\[[@B23],[@B24]\]^.

###### 

Comparison of clinicopathologic characteristics with age and tumor site in TNBC and nTNBC

  **Clinical features**   **TNBC**   **nTNBC**        
  ----------------------- ---------- ----------- ---- ------
  Age of diagnosis                                    
  \<46                    10         43.5        9    33
  \>46                    13         56.5        18   67
                                                      
  Site of tumor                                       
  Left                    13         56.5        15   55.5
  Right                   10         43.5        12   44.5
                                                      
  ER                                                  
  Negative                23         100         10   37
  Positive                0          0           17   63
                                                      
  PR                                                  
  Negative                23         100         14   50
  Positive                0          0           14   50
                                                      
  Her2 status                                         
  Negative                23         100         16   59.2
  Positive                0          0           11   40.8
                                                      
  Tumor size                                          
  ≤3                      12         52          14   52
  \>3                     11         48          13   48
                                                      
  Lymphatic invasion                                  
  Yes                     11         52          14   52
  No                      12         48          13   48
                                                      
  Perineural invasion                                 
  Yes                     9          39          8    29.5
  No                      14         61          19   70.5
                                                      
  Grade                                               
  Grade I + II            11         48          16   59.2
  Grade III               12         52          11   40.8
                                                      
  Necrosis                                            
  Yes                     15         65.2        10   37
  No                      8          34.8        17   63
                                                      
  Histological type                                   
  Ductal                  16         69.5        18   66.6
  Lobular                 5          21.7        7    25.9
  Other                   1          4.3         2    7.4
  Unknown                 1          4.3         0    \-

**Statistical analysis**

GraphPad Prism 7 was used for the statistical analysis. All data were expressed as mean ± standard error of three independent experiments, and *p* \< 0.05 was considered statistically significant. The ROC curve was constructed to establish a sensitivity-specificity relationship. Cut-off values that provided the best sensitivities and specificities were determined. The sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios, and accuracy were calculated^\[[@B25]\]^.
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**Ethical statement**

The above-mentioned sampling protocols were approved by the Regional Ethics Committee of Kurdistan University of Medical Sciences, Sanandaj, Iran (ethical code: IR.MUK.REC.1395/279). Written informed consents were obtained from all the participants before surgery.

RESULTS
=======

Fifty patients with breast cancer were included in the present study. Of these, 27 were nTNBC and 23 were TNBC. The expression level of HDAC8 increased significantly in the breast cancer samples compared to the normal tissue samples (0.5867 ± 0.023 vs. 0.4724 ± 0.024 \[ru\], respectively; *p* = 0.0011; [Fig. 1](#F1){ref-type="fig"}). The results of the HDAC8 expression in the TNBC and nTNBC groups revealed that HDAC8 gene expression in both groups altered significantly in comparison to the benign tissue (*p* \< 0.0001 and *p* = 0.04, respectively; [Fig. 2](#F2){ref-type="fig"}). Also, a significant elevation was observed in the expression of HDAC8 gene in TNBC compared to the nTNBC patients (0.6694 ± 0.02 vs. 0.5162 ± 0.03 \[ru\], respectively; *p* = 0.0013; [Fig. 2](#F2){ref-type="fig"}). The data showed that the overexpression of HDAC8 is a potential risk factor for the progression of TNBC (odds ratio = 6.729; 95% CI = 1.939-23.356; *p* = 0.002).

The association between HDAC8 expression and pathological outcomes was studied in the nTNBC and TNBC groups. In nTNBC patients, there was no significant relationship between HDAC8 expression and tumor characteristics, including tumor size (*p*= 0.1), lymphatic invasion (*p* = 0.06), tumor grade (*p* = 0.14), and perineural invasion (*p* = 0.2). However, in the TNBC group, a significant association was found between the increased HDAC8 expression and tumor characteristics, including tumor size (*p* = 0.039; [Fig. 3A](#F3){ref-type="fig"}), lymphatic invasion (*p* = 0.01, [Fig. 3B](#F3){ref-type="fig"}), tumor grade (*p* = 0.02; [Fig. 3C](#F3){ref-type="fig"}), and perineural invasion ( (*p* = 0.014; [Fig. 3D](#F3){ref-type="fig"}).

The diagnostic value of HDAC8, as a potential tumor marker, for the differentiation of nTNBC from TNBC subjects was investigated. The ROC curve was plotted, and the cut-off value was determined at 0.6279 (ru). Using that cut-off point, the AUC was 0.760 (95% CI = 0.624-0.896; [Fig. 4](#F4){ref-type="fig"}). According to the cut-off point, the diagnostic value was determined as follows: sensitivity (73.91%), specificity (70.37%), positive predictive value (0.68), negative predictive value (0.76), positive likelihood ratio (2.49), negative likelihood ratio (0.37), and accuracy (72%).

DISCUSSION
==========

Studies have revealed an oncogenic role for HDAC8 in the progression of breast cancer and have indicated the effect of this gene on TNBC. It has been shown that the *HDAC8* gene can regulate the biological function of cancer cells both in the cytoplasm and cell nucleus^\[[@B26],[@B27]\]^. Overexpression of HDAC8 has been found to increase the migration of breast cancer cells through the Hippo signaling pathway. Consequently, suppression of the HDAC8 gene has been proposed as a potential target for TNBC treatment^\[[@B28]\]^. WU *et al.*^\[[@B29]\]^ have disclosed that suberoylanilide hydroxamic acid inhibits HDAC8/FOXA1 signals in the epithelial-mesenchymal transition of cancer cells and introduced this acid as an anti-tumor agent for the treatment of TNBC cancer. HDAC8 also is involved in cellular invasion and expression of the MMP-9 gene in human cancer cells^\[[@B30]\]^. Hypomethylation of the HDAC8 promoter significantly enhances the expression of this oncogene in TNBC cells^\[[@B31]\]^. Overexpression of HDAC8 has been indicated to be associated with poor prognosis and drug resistance in breast cancer^\[[@B31]\]^. It has also been shown that the HDAC8 gene is involved in regulating P53 expression and suppressing HDAC8/YY1 signals that may reverse the tumorigenicity of mutant P53 in breast cancer^\[[@B32]\]^. In line with previous studies, the current findings suggested a significant elevation of HDAC8 in breast cancer tissue specimens compared to normal adjacent tissues samples. It was also found the expression of this gene in TNBC cancer is much higher than in nTNBC. More interestingly, there was a direct significant association with clinical outcomes in TNBC subjects.
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Despite the tumorigenicity of HDAC8, the value of this marker for use as a diagnostic tool has not yet been determined. On the other hand, the late diagnosis of TNBC increases the complexity of treatment, providing a poor prognosis for this type of cancer. Hence, it is necessary to develop new methods and novel tumor markers for early detection of TNBC.

To the best of our knowledge, this study, for the first time, assesses the diagnostic utility of HDAC8, as a potential tumor marker for differentiation of TNBC from nTNBC subjects. To date, no other published studies have been found on the value of HDAC8 in TNBC patients. The current study used a cut-off point of 0.6279 (ru) and sensitivity and specificity of 73.91% and 70.37%, for HDAC8, respectively.

The present study highlights the up-regulation of HDAC8 from tissue as a diagnostic and prognostic
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marker. It was possible to validate the overexpression of HDAC8 in breast cancer specimens; therefore, it was determined that HDAC8 is higher in TNBC samples than in nTNBC and benign tissue. A correlation between tissue levels of HDAC8 and clinical findings was observed in the TNBC patients in this study.

In conclusion, our data indicate the diagnostic value of HDAC8 in breast cancer patients and the results suggest that it could serve as a predictor of breast cancer development.
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